AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15656848
Drug: Relaxation breathing
RxNorm normalized name: cetylpyridinium chloride Mouthwash [Breath-Away]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Relaxation breathing exercise combined with physical exercise for 30 minutes daily for six weeks
Trial: 10456815
Drug: Ketamine (50,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (50, 100, and 200 ng x mL(‐1))
Trial: 10456815
Drug: Alfentanil (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfentanil (50 ng x mL(‐1))
Trial: 858795
Drug: Audiovisual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Audiovisual treatment depicting a dyadic psychotherapy situation with varying therapist age and status.
Trial: 28718236
Drug: Metformin Immediate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin Immediate Release (MIR) 1000 mg twice daily
Trial: 28718236
Drug: Metformin Extended
RxNorm normalized name: metFORMIN Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin Extended Release (MXR) 1000 mg twice daily
Trial: 28718236
Drug: Metformin Extended
RxNorm normalized name: metFORMIN Extended Release Suspension
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin Extended Release (MXR) 500 mg twice daily
Trial: 25371036
Drug: Fixed bladder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed bladder volume of 500 ml
Trial: 23573880
Drug: Bidirectional knotless
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bidirectional knotless barbed suture (0-Quill™; Angiotech Pharmaceuticals, Inc.)
Trial: 18215977
Drug: Lopinavir/ritonavir (LPV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lopinavir/ritonavir (LPV/r) therapy
Trial: 10892659
Drug: Losartan (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (50 mg/day for 3 days)
Trial: 8814373
Drug: Granisetron (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granisetron (single intravenous dose)
Trial: 8814373
Drug: Ondansetron (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (twice-daily oral for 3 or 4 days)
Trial: 24681179
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg parecoxib injection 30‐45 min before anesthesia induction and 4 ml saline injection when gallbladder was removed
Trial: 24681179
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml saline injection 30‐45 min before anesthesia induction and 40 mg parecoxib injection when gallbladder was removed
Trial: 24681179
Drug: 4 ml
RxNorm normalized name: ethanol 1.4 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 ml saline injection 30‐45 min before anesthesia induction and the time when gallbladder was removed
Trial: 22063735
Drug: Prednisolone treatment
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone treatment within the first week after onset of symptoms
Trial: 17636090
Drug: Ecopipam 100
RxNorm normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecopipam 100 mg daily for 12 weeks
Trial: 17636090
Drug: Ecopipam 100
RxNorm normalized name: Ecopipam
DrugBank: Ecopipam (DB12273)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ecopipam 100 mg daily for 52 weeks
Trial: 15691239
Drug: Inhaled hypertonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled hypertonic saline (4.5% for ≤ 15 min without bronchodilator pretreatment)
Trial: 15691239
Drug: Inhaled methacholine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled methacholine (maximum cumulative dose 4 micromol)
Trial: 10037073
Drug: G-CSF (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: G-CSF (100 to 250 microg) given daily until neutrophil counts rose to greater than 1000/microL
Trial: 10037073
Drug: Untreated group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Untreated group receiving antibiotic therapy only
Trial: 2033693
Drug: External sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External sequential pneumatic compression stockings
Trial: 2033693
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus dihydroergotamine
Trial: 6763394
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose tobramycin
Trial: 6763394
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose tobramycin
Trial: 6763394
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose amikacin
Trial: 6763394
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose amikacin
Trial: 22772870
Drug: S-pantoprazole 20
RxNorm normalized name: pantoprazole 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S-pantoprazole 20 mg
Trial: 17323787
Drug: Aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 650 mg (pretreatment)
Trial: 17323787
Drug: Aspirin 650
RxNorm normalized name: aspirin 650 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin 650 mg (concomitant treatment)
Trial: 17323787
Drug: Aspirin (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (both treatments)
Trial: 2754630
Drug: Nortriptyline treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nortriptyline treatment for seven weeks with plasma levels kept between 50‐180 ng/ml
Trial: 865738
Drug: General inhalation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General inhalation anesthesia
Trial: 865738
Drug: Analgesia and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Analgesia and General inhalation anesthesia
Trial: 12718225
Drug: Trimethazidine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimethazidine (20 mg thrice a day)
Trial: 11206600
Drug: sertraline, 50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline, 50 mg/day
Trial: 11206600
Drug: sertraline, 100
RxNorm normalized name: Sertraline, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline, 100 mg/day
Trial: 11206600
Drug: fluoxetine, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluoxetine, 20 mg/day
Trial: 11206600
Drug: sertraline, 100
RxNorm normalized name: Sertraline, 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline, 100 mg/day (after dose increase)
Trial: 11206600
Drug: sertraline, 200
RxNorm normalized name: Sertraline, 200 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sertraline, 200 mg/day (after dose increase)
Trial: 11206600
Drug: fluoxetine, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: fluoxetine, 40 mg/day (after dose increase)
Trial: 9313279
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream with suggestion that it might help reduce needle pain
Trial: 9313279
Drug: Placebo cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo cream with no indication of purpose
Trial: 9313279
Drug: Observer ratings
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observer ratings for cream plus suggestion
Trial: 9313279
Drug: Observer ratings
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observer ratings for cream alone
Trial: 25023055
Drug: No antiviral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No antiviral prophylaxis
Trial: 22613532
Drug: Anisodamine (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anisodamine (0.1 - 0.2 µg × kg(‐1)× min(‐1) intravenous infusion from PCI to 24 hours after PCI)
Trial: 20220748
Drug: Silodosin 24
RxNorm normalized name: Silodosin
DrugBank: Silodosin (DB06207)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Silodosin 24 mg
Trial: 18224311
Drug: Lansoprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (60 mg oral dose) with clarithromycin (800 mg/day)
Trial: 18224311
Drug: Lansoprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (60 mg oral dose) with fluvoxamine (50 mg/day)
Trial: 18224311
Drug: Lansoprazole (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (60 mg oral dose) with placebo
Trial: 12100205
Drug: Mycophenolate mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate mofetil (MMF) 1 g daily (follow-up)
Trial: 9589224
Drug: 20.7 mmol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20.7 mmol MgO daily for 30 days
Trial: 9589224
Drug: 41.4 mmol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 41.4 mmol MgO daily for 30 days
Trial: 8025966
Drug: Chemoembolization using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoembolization using ethiodized oil (Lipiodol) and anticancer agents (Mitomycin in 40 patients, DADH in 58 patients)
Trial: 27861700
Drug: Cholecalciferol 4,000
RxNorm normalized name: CHOLECALCIFEROL 4,000UNIT CAP,ORAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 4,000 IU daily for 9 months
Trial: 19858396
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m² with cisplatin 50 mg/m² (arm A)
Trial: 19858396
Drug: Gemcitabine 1,500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,500 mg/m² at a fixed dose rate of 10 mg/m²/min (arm B)
Trial: 19858396
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m² with docetaxel 40 mg/m² (arm C)
Trial: 19858396
Drug: Gemcitabine 1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemcitabine 1,000 mg/m² with irinotecan 100 mg/m² (arm D)
Trial: 14970134
Drug: Remifentanil by
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil by bolus injection
Trial: 11642083
Drug: Neoton therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoton therapy
Trial: 11642083
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (TLT) without neoton
Trial: 11642083
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (TLT) with streptokinase preparations
Trial: 11642083
Drug: Thrombolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thrombolytic therapy (TLT) with streptokinase preparations and neoton
Trial: 21531706
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment after first seizure
Trial: 8988885
Drug: Vaccine 1
RxNorm normalized name: TWINRIX vaccine 1 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine 1
Trial: 8988885
Drug: Vaccine 2
RxNorm normalized name: RABIES VACCINE 2.5UNT/VIL INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine 2
Trial: 8988885
Drug: Vaccine 3
RxNorm normalized name: LYME DISEASE VACCINE 30MCG/0.5ML INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine 3
Trial: 8233271
Drug: 500-mg naproxen
RxNorm normalized name: naproxen 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500-mg naproxen suppositories
Trial: 21034476
Drug: Goal-directed fluid
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal-directed fluid therapy (GDT) with individualized fluid replacement
Trial: 18763691
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg HPP-containing tablets
Trial: 18763691
Drug: 7 mg
RxNorm normalized name: pectin 7 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 mg HPP-containing tablets
Trial: 18763691
Drug: 0% HPP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0% HPP control tablets
Trial: 14602747
Drug: Phytoestrogen (114
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytoestrogen (114 mg isoflavonoids)
Trial: 10951436
Drug: deflazacort (0.9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: deflazacort (0.9 mg/kg/day)
Trial: 10951436
Drug: prednisone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: prednisone (0.75 mg/kg/day)
Trial: 8797398
Drug: Albuterol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (100 micrograms per puff, max 16 puffs)
Trial: 8797398
Drug: Albuterol (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albuterol (100 micrograms per puff)
Trial: 1474082
Drug: Naloxone (0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.4 mg/kg iv)
Trial: 6706302
Drug: Branched-chain enriched
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain enriched amino acid solution (BCAA, 80 gm per day)
Trial: 6706302
Drug: Branched-chain enriched
RxNorm normalized name: Machilus thunbergii branch extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Branched-chain enriched amino acid solution (BCAA)
Trial: 31814710
Drug: Apatinib as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib as maintenance therapy following chemotherapy
Trial: 31814710
Drug: Apatinib as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib as palliative following chemotherapy
Trial: 31814710
Drug: Apatinib alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib alone as salvage therapy
Trial: 29691947
Drug: Adolescent focused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adolescent focused therapy
Trial: 27252412
Drug: 600 μg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 μg GTL001 + imiquimod
Trial: 27252412
Drug: 600 μg
RxNorm normalized name: P.G. 600 KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 μg GTL001 + placebo cream
Trial: 22445475
Drug: Cockroft &
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cockroft & Gault (C&G)
Trial: 17680515
Drug: Sequential SV‐CABG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential SV‐CABG (seqSV‐CABG)
Trial: 17169645
Drug: Periprostatic infiltration
RxNorm normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic infiltration of 6 mL 1% lidocaine
Trial: 17169645
Drug: Periprostatic and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Periprostatic and apical infiltration: 4 mL 1% lidocaine at the prostate-seminal vesicle junction and 2 mL infiltration at the prostatic apex
Trial: 12578924
Drug: Voice Treatment
RxNorm normalized name: Accu-Chek Voicemate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice Treatment (VT) using the Lee Silverman Voice Treatment method
Trial: 12578924
Drug: Voice Treatment
RxNorm normalized name: Accu-Chek Voicemate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voice Treatment (VT)
Trial: 10494189
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose chemotherapy with autologous stem cell support
Trial: 31776726
Drug: R-GEM-L (lenalidomide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: R-GEM-L (lenalidomide + rituximab + methylprednisolone + gemcitabine)
Trial: 27030499
Drug: control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: control group (no IUD or steroids)
Trial: 15611795
Drug: Sequential MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential MTX (200 mg m(‐2) i.v. on days 1 and 15) followed by FU (600 mg m(‐2) i.v. on days 2 and 16) and LV rescue (15 mg p.o. q 6 h x 6 doses)
Trial: 15611795
Drug: 5-fluorouracil (370
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5-fluorouracil (370 mg m(‐2) i.v. bolus) preceded by leucovorin (100 mg m(‐2) i.v. bolus on days 1-5)
Trial: 8481662
Drug: High-dose cytosine
RxNorm normalized name: cytosine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cytosine arabinoside
Trial: 11587367
Drug: Incorporation of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incorporation of gemtuzumab zogamicin into treatment regimens
Trial: 9144906
Drug: Tolterodine 2
RxNorm normalized name: tolterodine 2 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine 2 mg b.i.d.
Trial: 16358396
Drug: Obese subjects
RxNorm normalized name: DIET FORMULATIONS FOR TREATMENT OF OBESITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Obese subjects with or without binge-eating disorder in single-item meal (ice cream)
Trial: 16358396
Drug: Non-obese controls
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-obese controls in single-item meal (ice cream)
Trial: 16358396
Drug: Patients with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with bulimia nervosa (BN) in single-item meal (ice cream)
Trial: 21915003
Drug: Infusion-site reactions
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infusion-site reactions (pain, erythema, swelling)
Trial: 17163239
Drug: Bendroflumethiazide 1.25
RxNorm normalized name: bendroflumethiazide 1.25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide 1.25 mg/day and potassium chloride
Trial: 17163239
Drug: Bendroflumethiazide 2.5
RxNorm normalized name: bendroflumethiazide 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide 2.5 mg/day and potassium chloride
Trial: 14557093
Drug: Oral objective-structured
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral objective-structured clinical examination (OSCE) sessions (oral)
Trial: 10746824
Drug: Glipizide (11
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glipizide (11 mg/day)
Trial: 10746824
Drug: Glyburide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide (10 mg/day)
Trial: 6460474
Drug: Acne treatment
RxNorm normalized name: Acne Treatment
DrugBank: Octasulfur (DB09353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acne treatment
Trial: 31984445
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg D-cycloserine
Trial: 21911655
Drug: 20 IU
RxNorm normalized name: Calcium/Phosphorus/Vitamin D 105 MG-81 MG-120 IU Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 IU of insulin
Trial: 21911655
Drug: 40 IU
RxNorm normalized name: Oxytocin 40 IU/1 ML Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 IU of insulin
Trial: 19444555
Drug: Landiolol hydrochloride
RxNorm normalized name: Landiolol Hydrochloride
DrugBank: Landiolol (DB12212)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Landiolol hydrochloride (0.125 mg x kg(‐1) x min(‐1) for 1 min, followed by 0.04 mg x kg(‐1) x min(‐1) infusion)
Trial: 17578462
Drug: NaCl 0.9%,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl 0.9%, 750 ml/m(2) body surface area (BSA)
Trial: 17578462
Drug: hydroxyethylic starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydroxyethylic starch 10%, 250 ml/m(2) BSA and NaCl 0.9%, 400 ml/m(2) BSA
Trial: 17578462
Drug: dextran 10%,
RxNorm normalized name: Dextran 10%, Dextrose 5% Solution for injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextran 10%, 250 ml/m(2) BSA and NaCl 0.9%, 300 ml/m(2) BSA
Trial: 17578462
Drug: hypertonic sodium
RxNorm normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypertonic sodium chloride 7.2%/hyperoncotic hydroxyethylic starch 10%, 150 ml/m(2) BSA
Trial: 17578462
Drug: hypertonic sodium
RxNorm normalized name: Sodium Chloride Topical application Dressing [CURITY HYPERTONIC SODIUM CHLORIDE PACKING STRIP]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hypertonic sodium chloride 7.2%/hyperoncotic dextran 10%, 150 ml/m(2) BSA
Trial: 9086315
Drug: NaCl (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NaCl (0.2 g/kg/day)
Trial: 2007961
Drug: 30 mmol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mmol/L alanine in WHO oral rehydration solution (ORS)
Trial: 2007961
Drug: Standard WHO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard WHO oral rehydration solution (ORS)
Trial: 6808838
Drug: Acyclovir 3
RxNorm normalized name: acyclovir 30 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir 3 percent ophthalmic ointment
Trial: 6808838
Drug: Trifluorothymidine 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trifluorothymidine 2 percent ointment
Trial: 28040502
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PAD) with toluidine blue (0.1mg/mL) and LED lamp (635nm, 200mW/cm2) for 60s
Trial: 28040502
Drug: Calcium hydroxide
RxNorm normalized name: Calcium Hydroxide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium hydroxide therapy (Ca(OH)2) for two weeks
Trial: 28040502
Drug: Comparison between
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison between PAD and calcium hydroxide therapy
Trial: 26335189
Drug: Homeopathic medication
RxNorm normalized name: homeopathic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic medication (IFC group: Influcid®) for 7 days plus standard treatment (paracetamol, ambroxol, and/or oxymetazoline)
Trial: 26335189
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (ST group: paracetamol, ambroxol, and/or oxymetazoline)
Trial: 26335189
Drug: Homeopathic medication
RxNorm normalized name: homeopathic medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Homeopathic medication (IFC group: Influcid®)